Abstract: Impaired healing of the skin is a notable cause of patient morbidity and mortality. In diabetic individuals, dysregulated inflammation contributes to delayed wound healing. Specific immunomodulatory agents may have a role in the treatment of diabetic wounds. One of these molecules is interleukin-1 receptor antagonist (Anakinra; Amgen Corp.). Although interleukin-1 receptor antagonist (Anakinra; Amgen Corp.) is approved by the Food and Drug Administration (FDA) for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease, little is known about the local use this drug in cutaneous wound healing. Therefore, the aim of this study is to determine the effect of locally administered interleukin-1 receptor antagonist on delayed wound healing, specifically, in a diabetic mouse model. Two 6-mm full-thickness wounds were created on the dorsa of diabetic (db/db) mice and stented. One-hour postwounding, wound margins were subcutaneously injected with either (1) low-dose interleukin-1 receptor antagonist in a gelatin-transglutaminase gel vehicle or (2) the gel vehicle only. Wounds were imaged on days 0, 7, 14, and 21 postwounding, and wound area was determined. Wound biopsies were collected on day 21 and immunohistochemically stained for neutrophil and macrophage infiltration. Wounds treated with interleukin-1 receptor antagonist had significantly smaller wound area than nontreated wounds on day 7 and day 14 postwounding. Treated wounds also showed significantly less neutrophil and macrophage infiltration. These findings support the hypothesis that interleukin-1 receptor antagonist may have an important role in cutaneous wound healing, possibly by promoting successful resolution of acute inflammation and hence accelerating wound closure. Thereby, administration of IL-1Ra may be useful in the treatment of nonhealing wounds.
T he skin barrier is an important component of human health. Subsequently, impaired healing of the skin is a notable cause of patient morbidity and even mortality. In the United States, chronic wounds affect more than 6.5 million patients, and 1% to 2% of the US population will experience a chronic wound in their lifetime. 1 Restoring functional wound healing or influencing the wound-healing process to act in a regenerative fashion therefore has multiple benefits relating to quality of life and health care cost.
Although not completely understood, the importance of the immune system in wound healing has been well established. Wound healing is divided into 4 phases: hemostasis, inflammation, proliferation, and remodeling. These phases, the wound-healing cascade, are controlled by a complex set of signals from the wound and its microenvironment. Hemostasis is controlled by reflex vasoconstriction and the components of the coagulation cascade, resulting in a clot and the release of proinflammatory cytokines. Inflammation, also triggered directly by tissue injury, is important in readying the wound for closure. It is regulated by cell signaling molecules and is characterized by classic clinical observations-rubor, tumor, calor, and dolor-as well as a predictable pattern of infiltration from different immune cell types. 2 The cell signaling molecules released, namely, cytokines, chemokines, and growth factors, are released by both resident cells as well as newly arrived leukocytes. 3 The proliferative phase results in wound closure and is followed by remodeling, during which the components of the closed wound are turned over and the tensile strength of the scar is increased. 4 The events of the inflammatory phase have a profound effect on final wound outcome, such that an abnormal inflammatory response will result in abnormal wound healing 3, 5 Therefore, molecules that regulate the inflammatory phase of the wound-healing cascade are potential therapeutic targets for improved wound healing. One of these molecules is interleukin-1 receptor antagonist (IL-1Ra).
The IL-1Ra is a potent regulator of Interleukin-1 (IL-1) and therefore modulates a variety of inflammatory events. In fact, IL-1Ra (Anakinra; Amgen Corp., Thousand Oaks, CA) has been approved by the FDA for treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease. The role of IL-1Ra as a regulator of inflammation suggests that it may be useful in therapies to improve wound healing. In addition, a few studies have shown that the disruption of IL-1 signaling can improve wound healing and reduce scaring. 6, 7 Little is known, however, about the local use of IL-1Ra in cutaneous wound healing. Therefore, the aim of this study was to determine the effect of locally administered IL-1Ra on wound healing in a diabetic mouse model.
METHODS

Excisional Wound Model
All animal procedures were approved by the Institutional Animal Care and Use Committee at the University of Southern California (protocol ID 20168). A splinted excisional wound model was used to more closely simulate human wound healing, specifically, to promote healing by reepithelialization and granulation tissue formation. 8 Male diabetic mice (db/db; BKS.Cg-m +/+ Lepr db ; Jackson Laboratories, Bar Harbor, ME) were used. Mice were 14 to 17 weeks old at the time of experiment and weighed 51 to 60 g. Mice were anesthetized using continuous nasal administration of Isoflurane (1-4% in oxygen) and kept on a heating pad for the duration of the procedure. The dorsum of each mouse was shaved with an electric clipper, rinsed with alcohol, and sterilely prepped with providone-iodine and draped. A sterile 6-mm punch biopsy was used to create 2 full-thickness wounds on each experimental animal (n = 7). Wounds were stented with 7-mm circular silicone wound splints (Grace Bio-Labs, Bend, Oregon) and the splints were secured with Krazy Glue (Elmer's Inc., Columbus, OH) and interrupted 6-0 prolene sutures (Ethicon, Inc., Somerville, NJ). One-hour postwounding, wound margins were subcutaneously injected in a circumferential fashion with 70 μL of either (1) low-dose IL-1Ra (5 μL anakinra, 0.75 mg IL-1Ra) in a 3% gelatin-transglutaminase (TGase) gel vehicle or (2) TGase gel only. On each animal, 1 wound was treated with IL-1Ra and the other with the gel vehicle to serve as the control carrier. An optimal dose for localized application of IL1-Ra for wound healing has not yet been well described. The dose used in this study was chosen based on unpublished work from a collaborator studying the effect of IL-1Ra on nondiabetic wound healing. The TGase gel vehicle was used to maximize the local half-time of IL-1Ra. 9 Wounds were then digitally imaged and dressed with Telfa (Covidien, Minneapolis, MN), Tegaderm (3M, St. Paul, MN), and Coban (3M, St. Paul, MN) to deter gnawing/scratching of wounds. Dressings were changed every 7 days or if they were found to be soiled or not intact on daily examination. Animals were allowed to recover, then housed individually to prevent wound disturbance. Animal care was performed by the institutional animal care facility. Biopsies were taken of the wound area and the surrounding skin on day 21, at which point the animals were euthanized with intraperitoneal pentobarbital (100-200 mg/kg) followed by cervical dislocation. Tissue specimens were fixed in 4% formaldehyde for 24 hours and embedded in paraffin. Paraffin sections were stained with hematoxylin and eosin or used for immunohistochemical analysis.
Wound Imaging and Analysis
Wounds were digitally imaged directly after stent placement and then every 7 days until cessation of the experiment on day 21. The 7-day time interval between wound imaging was chosen to minimize manipulation of the wound upon dressing removal. Wound healing studies with shorter intervals between wound area quantification have already been reported. 6 A Nikon D3000 with a Canfield Imaging System was used to capture standardized photographs. Wound areas were traced manually in an image analysis program (ImageJ v10.2, NIH) and splint diameter was used to calibrate measurements. Percent of original size of each wound was calculated and data were analyzed and plotted in Prism 6 (Graphpad Software Inc.).
Immunohistochemistry
Anti-myeloperoxidase (MPO) antibodies (AF3667; R&D Systems, Minneapolis, MN) were used to stain for neutrophils (diluted 1:500). Secondary anti-goat antibodies were used from the VECTASTAIN Elite ABC kit (Goat IgG). Anti-F4/80 Antibodies (ab6640, Abcam) were used to assess for macrophages (diluted 1:500). Anti-Rat IgG (H + L) (Vector Laboratories) was used as the secondary antibody (diluted 1:500). The VECTASTAIN Elite ABC kit was used to control background stain in all immunohistochemistry preparations. Dilutions were made with 5% mouse serum in PBS for Anti-MPO and Secondary Antigoat IgG and with 1% mouse serum in PBS for Anti-F4/80 and Anti-Rat IgG. Prepared tissue specimens were imaged with a Carl Zeiss Axio Scope and an Olympus DP72 camera. Five photographs were taken of each specimen, and the number of macrophages and neutrophils in each image were independently scored by two blinded reviewers. Data were analyzed and plotted in Prism 6 (Graphpad Software Inc.).
Statistical Analysis
Statistical analysis was performed in Prism 6. Wound closure data were analyzed by multiple t tests, and multiple comparisons were corrected for with the Holm-Sidak method. Immunohistochemistry data were analyzed with unpaired t tests. A probability (P) value <0.05 was considered significant. All values are expressed as mean ± SEM.
Results
IL-1Ra Therapy Decreases Time to Closure in Splinted Diabetic Wounds
Diabetes leads to abnormal wound healing in part due to immune cell dysfunction. As such, we wished to determine the effect of local administration of the immunomodulatory agent IL1-Ra on diabetic wounds using the well established db/db mouse model. IL-1Ra-treated wounds healed at a significantly greater rate than placebo-treated wounds. Specifically, IL1-Ra-treated wounds had significantly reduced wound area compared to placebo-treated wounds, at 7 days and 14 days (P < 0.02 and P < 0.03, respectively). Although this trend continued at 21 days, the difference between IL-1Ra-and placebo-treated wounds did not reach statistical significance (P = 0.13). (Figs. 1 and 2 ).
IL-1Ra Therapy Is Associated With Significantly Less Inflammation in Diabetic Wounds
Given the role of IL-1Ra in regulating local inflammation via IL-1, we were interested in characterizing changes in the inflammatory infiltrate after treatment. Neutrophils were identified by staining for MPO and macrophages were identified by staining for anti-F4/80. There was significantly less neutrophil (P < 0.001) and macrophage FIGURE 1. IL-1Ra-treated wounds healed faster than placebo-treated wounds. Photographs of full-thickness skin wounds treated with either IL-1Ra or the gel vehicle. Two wounds were created in each animal, one wound was treated with IL-1Ra and the other with the placebo. Wounds were then photographed every seven days until wound closure and compared. Inside diameter of the splint is 7 mm. Images of one representative experiment is shown. infiltration (P < 0.02) in the IL-1Ra-treated wounds compared to the placebo-treated wounds (Figs. 3, 4 , 5, and 6).
DISCUSSION
Wound Model Rationale
A diabetic mouse model was chosen for two reasons. First, diabetes is common and affects more than 23 million people in the United States and 25% of all diabetics will develop foot ulcers. More so, 67% of all lower extremity amputations are seen in patients with diabetes. 1 Second, diabetic wounds are a prime example of impaired healing resulting from aberrations in multiple processes. Examples include vascular disease, impaired granulocytic function, prolonged inflammation, defective neovascularization, decreased collagen synthesis, increased proteinases, and impaired macrophage function. 10 
IL-1Ra and Inflammation
The IL-1Ra is a naturally occurring protein that regulates inflammation by inhibiting receptors of IL-1α and IL-1β, collectively referred to as IL-1. IL-1 is a cytokine involved in a range of activities important in immunity, injury, and inflammation. 11 These include induction of cytokine and growth factor release, expression of endothelial adhesion molecules, polymorphonuclear, and macrophage chemotaxis, and keratinocyte mitogenesis, migration, and secretion of proinflammatory cytokines. 12 The integral involvement of IL-1 in immune system function suggests that IL-1Ra has a similarly important role. This is clinically evident by the use of IL-1Ra for treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease, both disorders of dysfunctional inflammation. In addition, IL-1Ra is currently being studied in a range of other inflammatory conditions including the neuroinflammatory response in traumatic brain injury, hypersensitivity reactions, and tissue remodeling after myocardial infarction. [13] [14] [15] Ultimately, the role of IL-1Ra in inflammation is good cause to consider it as a possible therapy for nonhealing wounds in addition to the other mentioned diseases.
IL-1Ra and Wound Healing
An abnormal inflammatory response results in abnormal wound healing. Although inflammation is a necessary component of healing, persistent inflammation will result in delayed wound closure. 4 Therefore, proinflammatory cytokines play an important role in wound repair, one example being they are greatly upregulated during the inflammatory phase of wound healing. 16 Of the proinflammatory cytokines, IL-1 is the first detectable upregulated cytokine after wound creation. 17 Neutrophils, macrophages, and resident cells all contribute to the expression of IL-1. 16 A variety of evidence already exists supporting the role of IL-1 signaling in wound healing. For example, impaired IL-1 signaling has been shown to accelerate wound healing in a mouse model. 6, 7 In contrast, unopposed IL-1 signaling in mice deficient in IL-1Ra have delayed wound healing. 18 The IL-1Ra, therefore, appears necessary to successful healing in vivo. More so, IL-1Ra has a role in the improved healing observed in human oral mucosa and the beneficial effect of mesenchymal skin cells on cutaneous wounds. The IL-1Ra is upregulated in the mesenchymal skin cells derived from human oral mucosa, a tissue that heals faster and with less scaring than skin (results not published). For these reasons, IL-1Ra is of particular interest regarding inhibition of IL-1 signaling to improve healing.
In the context of chronic wounds, IL-1Ra may be beneficial across a range of chronic wound types. Chronic wounds can result from any disruption in the normal wound healing cascade. Therefore, a wide variety of conditions are associated with abnormal wound healing. In general, poorly healing states are propagated by a combination of multiple physiologic and biochemical insults to the wound healing process which tend to be specific to the particular condition. Common features seen across the range of chronic wound types would be the ideal targets for improving wound healing, however, they have been difficult to identify. 19 It has been suggested that persistent inflammation is a hallmark of chronic wounds; therefore, modulation of the inflammatory process Wound area of IL-1Ra-treated wounds (n = 7) was significantly reduced compared to placebo-treated wounds on days 7 (P < 0.02) and 14 (P < 0.03). There reduction in wound area on day 21 was not significantly reduced (P = 0.13). Photographs of wound areas were quantified in image J. Data reported as mean ± SEM.
may be an ideal target for multiple chronic wound types. 19 For example, with a drug, such as IL-1Ra. However, given the diversity of conditions associated with chronic wounds, a disease specific approach to therapy would clearly be the most efficacious option. Consistent with this concept, as will be described in greater detail below, we believe that in addition to being a potential therapy for multiple chronic wound types, IL-1Ra may be particularly effective for diabetic wounds given the specific role of macrophage dysfunction and the IL-1 pathway in these wounds.
Results and Significance
The experiments reported were performed to assess the possible role of locally delivered IL-1Ra in the treatment of non-healing wounds. In these experiments, wounds treated with IL-1Ra healed at a faster rate than the wounds treated with placebo. Wounds treated with IL-1Ra also demonstrated less neutrophil and macrophage infiltrate on biopsy, 21 days after wounding. These results are consistent with the previously mentioned studies regarding wound healing. In addition, these findings suggest that a disruption in IL-1 signaling shortly after wounding can have significant effects on final wound outcome.
The IL-1Ra-treated wounds demonstrated accelerated healing and decreased neutrophil infiltration. Therefore, we propose that IL-1Ra accelerates the healing process by limiting the initial inflammatory burden in the wound. IL-1Ra does this by inhibiting the IL-1-mediated expression of intercellular adhesion molecules on vascular endothelium, thereby inhibiting neutrophil chemotaxis. 20 Although neutrophils are an important defense against microbial infection, the toxic products that are produced by the neutrophil to kill phagocytosed microorganisms can escape the cell and damage surrounding tissue. 20 This would exacerbate the disease process. Therefore, less neutrophilic infiltrate translates to less tissue damage and improved healing. Note that it has been previously shown that neutrophil depletion accelerates healing, likewise, that neutrophils are deleterious to wound closure. 21 Decreasing the inflammatory burden in the wound area does more than just prevent further tissue damage from neutrophil products; it will also decrease the phagocytic load for macrophages. In normal wound healing, neutrophils are the first cells to arrive to the site of injury. After performing their function, the cells will subsequently undergo apoptosis. Macrophages will then infiltrate the tissue and peak in number around 3 to 5 days after tissue injury. A primary function of these macrophages is to remove apoptotic neutrophils and necrotic debris. If this debris is not removed, proinflammatory cytokines remain elevated, inflammation is prolonged, and healing is delayed. 22 Therefore, by decreasing the number apoptotic neutrophils needed to be cleared, inflammation should resolve more quickly and healing should be accelerated. It should also be noted that one of the characteristics of non-healing wounds in diabetic individuals is the presence of increased apoptotic cell load. This is a result of impaired apoptotic cell clearance by macrophages. 20 Therefore, it is reasonable to conclude that in diabetic mice, treatment with IL-1Ra would be especially therapeutic, as observed in our experiments.
The IL-1Ra-treated wounds also demonstrated less macrophage infiltration on day 21 postwounding. We propose that this observation is directly related to the how far the wound has progressed in the woundhealing cascade. In other words, that treated wounds are at a more mature stage of healing and, resultantly, display fewer macrophages. We do not believe that the decreased number of macrophages is a direct effect IL-1Ra on macrophage infiltration. In contrast to the almost instant response of neutrophils to injury, macrophages are not a predominant cell type until 3 to 5 days after injury. The effects of IL-1Ra on macrophage chemotaxis could be limited by the half-life of locally administered IL-1Ra. It should be noted, however, that IL-1β signaling has been shown to contribute to a persistent proinflammatory wound macrophage phenotype in diabetic wounds. 7 Furthermore, these authors showed that inhibition of IL-1β signaling was sufficient to induce a macrophage phenotype switch from a proinflammatory to a healingassociated state, which was associated with improved healing in diabetic mice. This suggests that IL-1Ra mediated IL-1 inhibition may likewise have a positive impact on macrophage phenotype, and therefore be a prime topic for further study.
It is of interest that a single dose of IL-1Ra 1 hour postwounding resulted in improved wound closure and decreased inflammation 21 days after wound creation and treatment. This highlights the importance of the events in the inflammatory phase of healing for final wound outcome. The large impact of a single dose may be explained by the previously described mechanism. Specifically, that by decreasing the initial burden of inflammatory cells there is less neutrophil mediated tissue damage and less apoptotic neutrophils left for macrophages to clear.
The limitations of this study include a small sample size and the relatively wide interval between wound photography. No change in behavior or cutaneous side effects of IL-1Ra were noted in our animals. In humans, systemic use of the medication does increase the risk of injection site reaction, infection, headache, nausea, and diarrhea. 23 In conclusion, our findings support the hypothesis that IL-1Ra may have an important role in cutaneous wound healing, by promoting successful resolution of acute inflammation leading to accelerated wound closure. Because IL-1Ra is already an FDA-approved drug, our results have significant impact since it could easily be repurposed to treat non-healing wounds in patients with diabetes or other known co-morbid risk factors. Our future work includes confirmation of our findings in a nonrodent wound healing model, such as mini pig. Although more data on minimal effective dose, optimal timing, and mechanism of action will be required before human clinical trials, IL-1Ra has the potential to be translated into a therapy that will augment our current arsenal of agents against refractory wounds.
